Department of Oral Biological and Medical Sciences, Faculty of Dentistry, The University of British Columbia, Vancouver, British Columbia, Canada.
BC Oral Cancer Prevention Program, Cancer Control Research, Vancouver, British Columbia, Canada.
Cancer Prev Res (Phila). 2021 Dec;14(12):1111-1118. doi: 10.1158/1940-6207.CAPR-21-0134. Epub 2021 Aug 10.
Most oral cancers arise from oral potentially malignant lesions, which show varying grades of dysplasia. Risk of progression increases with increasing grade of dysplasia; however, risk prediction among oral low-grade dysplasia (LGD), that is, mild and moderate dysplasia can be challenging as only 5%-15% transform. Moreover, grading of dysplasia is subjective and varies with the area of the lesion being biopsied. To date, no biomarkers or tools are used clinically to triage oral LGDs. This study uses a combination of DNA ploidy and chromatin organization (CO) scores from cells obtained from lesion brushings to identify oral LGDs at high-risk of progression. A total of 130 lesion brushings from patients with oral LGDs were selected of which 16 (12.3%) lesions progressed to severe dysplasia or cancer. DNA ploidy and CO scores were analyzed from nuclear features measured by our in-house DNA image cytometry (DNA-ICM) system and used to classify brushings into low-risk and high-risk. A total of 57 samples were classified as high-risk of which 13 were progressors. High-risk DNA brushing was significant for progression ( = 0.001) and grade of dysplasia ( = 0.004). Multivariate analysis showed high-risk DNA brushing showed 5.1- to 8-fold increased risk of progression, a stronger predictor than dysplasia grading and lesion clinical features. DNA-ICM can serve as a non-invasive, high-throughput tool to identify high-risk lesions several years before transformation. This will help clinicians focus on such lesions whereas low-risk lesions may be spared from unnecessary biopsies. DNA ploidy and chromatin organization of cells collected from oral potentially malignant lesions (OPMLs) can identify lesions at high-risk of progression several years prior. This non-invasive test would enable clinicians to triage high-risk (OPMLs) for closer follow-up while low-risk lesions can undergo less frequent biopsies reducing burden on healthcare resources.
大多数口腔癌是由口腔潜在恶性病变引起的,这些病变表现出不同程度的异型增生。异型增生程度越高,进展的风险就越大;然而,对于口腔低级别异型增生(LGD),即轻度和中度异型增生的风险预测可能具有挑战性,因为只有 5%-15%会转化。此外,异型增生的分级是主观的,并且因活检的病变部位而异。迄今为止,临床上没有使用生物标志物或工具来对口腔 LGD 进行分类。本研究使用来自病变刷取物的细胞的 DNA 倍体和染色质组织(CO)评分的组合来识别具有高进展风险的口腔 LGD。共选择了 130 例来自口腔 LGD 患者的病变刷取物,其中 16 例(12.3%)病变进展为重度异型增生或癌症。通过我们内部的 DNA 图像细胞计量学(DNA-ICM)系统分析核特征的 DNA 倍体和 CO 评分,并用于将刷取物分类为低风险和高风险。共有 57 个样本被归类为高风险,其中 13 个为进展者。高风险 DNA 刷检与进展( = 0.001)和异型增生分级( = 0.004)显著相关。多变量分析显示,高风险 DNA 刷检显示进展的风险增加了 5.1-8 倍,比异型增生分级和病变临床特征更强的预测因素。DNA-ICM 可以作为一种非侵入性、高通量的工具,在转化前几年识别高危病变。这将帮助临床医生关注这些病变,而低风险病变可能免受不必要的活检。从口腔潜在恶性病变(OPML)中收集的细胞的 DNA 倍体和染色质组织可以在几年前识别出有进展高风险的病变。这种非侵入性测试将使临床医生能够对高危(OPML)进行分类,以便进行更密切的随访,而低风险病变可以进行较少的频繁活检,从而减少医疗资源的负担。